-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACTUS-101 in Pompe Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ACTUS-101 in Pompe Disease Drug Details: ACTUS-101 is under development for the treatment of Pompe disease....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CELZ-001 in Type 2 Diabetes
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.CELZ-001 in Type 2 DiabetesDrug Details:CELZ-001 is under development for the treatment of type-2 diabetes. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VAC-85135 in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.VAC-85135 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details:VAC-85135 is under development for the treatment of essential...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – OX-640 in Anaphylaxis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.OX-640 in Anaphylaxis Drug Details:Epinephrine is under development for the treatment of allergic reactions, including anaphylaxis....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AB-1003 in Limb-Girdle Muscular Dystrophy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.AB-1003 in Limb-Girdle Muscular DystrophyDrug Details:AB-1003 is under development for the treatment of limb-girdle muscular dystrophy....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AB-1005 in Parkinson’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-1005 in Parkinson's Disease Drug Details: Gene therapy is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AB-1005 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AB-1005 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drug Details:...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SKL-27969 in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SKL-27969 in Triple-Negative Breast Cancer (TNBC) Drug Details:SKL-27969 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Carfostin in Congestive Heart Failure (Heart Failure)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Carfostin in Congestive Heart Failure (Heart Failure) Drug Details:Carfostin (BNP-CHF) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TQB-2618 in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TQB-2618 in Melanoma Drug Details: TQB-2618 is under development for the treatment of advanced solid...
-
Sector Analysis
Medical Tourism Market Trends and Analysis by Region, Provider, Service (Medical Treatment and Wellness) and Segment Forecast to 2027
Accessing the in-depth insight from the ‘Medical Tourism’ report can help you: Make informed decisions about market entry, opportunities, and traveler spending patterns Identify your competitors' capabilities to stay ahead in the market Identify promising segment analysis (Medical Treatment and Wellness), growth trends, regional trends, and markets to expand your regional presence, product portfolio, or successful investment Anticipate expected changes in demand and adjust your business development strategies How is our ‘Medical Tourism’ report different from other reports in the market? The report presents in-depth market sizing and...
-
Product Insights
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease pipeline market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gene Therapy Programs for Multiple System Atrophy and Parkinson’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Gene Therapy Programs for Multiple System Atrophy and Parkinson's Disease Drug Details Gene therapy...
-
Product Insights
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple System Atrophy Drugs in Development Market Overview Multiple System Atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs the body's involuntary functions (blood pressure, heart rate, bladder function, and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence, and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson medications. The Multiple System Atrophy pipeline drugs market research report provides comprehensive information on the therapeutics under development for MSA and analysis by stage of development,...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – ACTUS-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ACTUS-101 Drug Details ACTUS-101 is under development for the treatment of Pompe disease. The...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – Carfostin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Carfostin Drug Details Carfostin (BNP-CHF) is under development for the treatment of advanced stage...
-
Product Insights
Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Muscular Dystrophy Pipeline Drugs Market Report Overview Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The report titled ‘Muscular Dystrophy –Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update’, provides an overview of...
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Pompe Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Pompe disease is an inherited disorder caused by a defect in a gene called GAA. The GAA gene is responsible for the production of the GAA enzyme (acid alpha-glucosidase). The Pompe Disease pipeline drugs market research report outlays comprehensive information on the Pompe Disease targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type, that are being developed by companies/universities. It also reviews key players involved in Pompe Disease...
-
Product Insights
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Glial Cell Line Derived Neurotrophic Factor – Drugs In Development, 2022, outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.